BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
30.00
-0.10 (-0.33%)
At close: Sep 4, 2025
-0.33%
Market Cap174.70M
Revenue (ttm)1.21M
Net Income (ttm)-18.72M
Shares Out5.82M
EPS (ttm)-5.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,199
Average Volume5,120
Open31.60
Previous Close30.10
Day's Range30.00 - 31.60
52-Week Range24.40 - 37.00
Betan/a
RSI53.40
Earnings DateSep 10, 2025

About BioVersys AG

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 27
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.